Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara
→ Astellas and FibroGen are reporting that their fourth late-stage study of roxadustat hit the primary endpoint for anemia in patients with CKD.
→ North Carolina’s vTv Therapeutics watched its stock $VTVT soar over 40% on the news that its entered a licensing deal with Newsoara Biopharma. The agreement allows Newsoara to develop and commercialize vTv’s PDE4 inhibitor program in China, Hong Kong, Macau, Taiwan, and other Pacific Rim countries. Newsoara will develop the clinical stage drug, called HPP737, for respiratory and other inflammatory diseases, according to a company statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
